FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947361149> ?p ?o ?g. }

• W2947361149 endingPage "4073" @default.
• W2947361149 startingPage "4073" @default.
• W2947361149 abstract "4073 Background: Oral multikinase inhibitors that have shown improvements in overall survival (OS) in HCC are associated with clinically important toxicities that commonly require dose adjustment or discontinuation (D/C) due to intolerance. REACH and REACH-2 studied RAM in patients (pts) with HCC who progressed on or were intolerant to sorafenib (SOR), and REACH-2 only enrolled pts with baseline AFP ≥400 ng/mL. In REACH-2 RAM treatment (trt) improved OS compared to placebo (P), supporting findings in REACH pts with baseline AFP ≥400 ng/mL. An exploratory analysis of outcomes by reason for D/C of SOR was performed. Methods: Pts had advanced HCC, Child-Pugh A, ECOG PS 0-1, and prior SOR. Pts were randomized to RAM 8 mg/kg or P Q2W. A pooled independent pt data analysis (stratified by study) of REACH-2 and REACH pts (AFP ≥400 mg/mL) was performed. Results are reported by reason for SOR D/C (intolerance or disease progression). OS and PFS were evaluated using Kaplan-Meier method and Cox proportional hazard model. Objective response rate (ORR), disease control rate (DCR) and safety are reported. Results: Baseline characteristics in the pooled population were generally balanced between trt arms in each subgroup. Median durations of prior SOR were 2.5 mo for SOR intolerant (n = 70) and 4.0 mo for SOR progressors (n = 472). Median OS (RAM v P) was 10.2 v 6.7 mo for SOR intolerant and 8.0 v 4.7 mo for SOR progressors (Table). Rates of D/C due to trt-related adverse events (AEs) (Table) (7% in each subgroup), and Grade ≥3 AEs (most frequently hypertension) were consistent with those observed in each study. Conclusions: Acknowledging limitations of sample size, the RAM trt benefit in SOR intolerant pts was consistent with that in the ITT population. RAM was well tolerated in SOR intolerant pts with low rates of D/C due to related-AEs. Clinical trial information: NCT01140347, NCT02435433. [Table: see text]" @default.
• W2947361149 created "2019-06-07" @default.
• W2947361149 creator A5005925636 @default.
• W2947361149 creator A5007466199 @default.
• W2947361149 creator A5015598872 @default.
• W2947361149 creator A5017429888 @default.
• W2947361149 creator A5020551368 @default.
• W2947361149 creator A5022288769 @default.
• W2947361149 creator A5028950420 @default.
• W2947361149 creator A5032900701 @default.
• W2947361149 creator A5033735284 @default.
• W2947361149 creator A5039119608 @default.
• W2947361149 creator A5050715724 @default.
• W2947361149 creator A5061222063 @default.
• W2947361149 creator A5073864381 @default.
• W2947361149 creator A5073989429 @default.
• W2947361149 creator A5080340887 @default.
• W2947361149 creator A5082309779 @default.
• W2947361149 creator A5083536113 @default.
• W2947361149 creator A5085131013 @default.
• W2947361149 creator A5088566246 @default.
• W2947361149 creator A5090832721 @default.
• W2947361149 date "2019-05-20" @default.
• W2947361149 modified "2023-10-17" @default.
• W2947361149 title "Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2)." @default.
• W2947361149 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.4073" @default.
• W2947361149 hasPublicationYear "2019" @default.
• W2947361149 type Work @default.
• W2947361149 sameAs 2947361149 @default.
• W2947361149 citedByCount "5" @default.
• W2947361149 countsByYear W29473611492020 @default.
• W2947361149 countsByYear W29473611492021 @default.
• W2947361149 countsByYear W29473611492022 @default.
• W2947361149 crossrefType "journal-article" @default.
• W2947361149 hasAuthorship W2947361149A5005925636 @default.
• W2947361149 hasAuthorship W2947361149A5007466199 @default.
• W2947361149 hasAuthorship W2947361149A5015598872 @default.
• W2947361149 hasAuthorship W2947361149A5017429888 @default.
• W2947361149 hasAuthorship W2947361149A5020551368 @default.
• W2947361149 hasAuthorship W2947361149A5022288769 @default.
• W2947361149 hasAuthorship W2947361149A5028950420 @default.
• W2947361149 hasAuthorship W2947361149A5032900701 @default.
• W2947361149 hasAuthorship W2947361149A5033735284 @default.
• W2947361149 hasAuthorship W2947361149A5039119608 @default.
• W2947361149 hasAuthorship W2947361149A5050715724 @default.
• W2947361149 hasAuthorship W2947361149A5061222063 @default.
• W2947361149 hasAuthorship W2947361149A5073864381 @default.
• W2947361149 hasAuthorship W2947361149A5073989429 @default.
• W2947361149 hasAuthorship W2947361149A5080340887 @default.
• W2947361149 hasAuthorship W2947361149A5082309779 @default.
• W2947361149 hasAuthorship W2947361149A5083536113 @default.
• W2947361149 hasAuthorship W2947361149A5085131013 @default.
• W2947361149 hasAuthorship W2947361149A5088566246 @default.
• W2947361149 hasAuthorship W2947361149A5090832721 @default.
• W2947361149 hasConcept C126322002 @default.
• W2947361149 hasConcept C142724271 @default.
• W2947361149 hasConcept C143998085 @default.
• W2947361149 hasConcept C204787440 @default.
• W2947361149 hasConcept C207103383 @default.
• W2947361149 hasConcept C27081682 @default.
• W2947361149 hasConcept C2778019345 @default.
• W2947361149 hasConcept C2778695046 @default.
• W2947361149 hasConcept C2778715236 @default.
• W2947361149 hasConcept C2779551604 @default.
• W2947361149 hasConcept C2908647359 @default.
• W2947361149 hasConcept C3019894029 @default.
• W2947361149 hasConcept C44249647 @default.
• W2947361149 hasConcept C71924100 @default.
• W2947361149 hasConcept C90924648 @default.
• W2947361149 hasConcept C99454951 @default.
• W2947361149 hasConceptScore W2947361149C126322002 @default.
• W2947361149 hasConceptScore W2947361149C142724271 @default.
• W2947361149 hasConceptScore W2947361149C143998085 @default.
• W2947361149 hasConceptScore W2947361149C204787440 @default.
• W2947361149 hasConceptScore W2947361149C207103383 @default.
• W2947361149 hasConceptScore W2947361149C27081682 @default.
• W2947361149 hasConceptScore W2947361149C2778019345 @default.
• W2947361149 hasConceptScore W2947361149C2778695046 @default.
• W2947361149 hasConceptScore W2947361149C2778715236 @default.
• W2947361149 hasConceptScore W2947361149C2779551604 @default.
• W2947361149 hasConceptScore W2947361149C2908647359 @default.
• W2947361149 hasConceptScore W2947361149C3019894029 @default.
• W2947361149 hasConceptScore W2947361149C44249647 @default.
• W2947361149 hasConceptScore W2947361149C71924100 @default.
• W2947361149 hasConceptScore W2947361149C90924648 @default.
• W2947361149 hasConceptScore W2947361149C99454951 @default.
• W2947361149 hasIssue "15_suppl" @default.
• W2947361149 hasLocation W29473611491 @default.
• W2947361149 hasOpenAccess W2947361149 @default.
• W2947361149 hasPrimaryLocation W29473611491 @default.
• W2947361149 hasRelatedWork W166409149 @default.
• W2947361149 hasRelatedWork W1972665675 @default.
• W2947361149 hasRelatedWork W2327375634 @default.
• W2947361149 hasRelatedWork W2330289123 @default.
• W2947361149 hasRelatedWork W2983005864 @default.
• W2947361149 hasRelatedWork W3008936374 @default.
• W2947361149 hasRelatedWork W3149838050 @default.
• W2947361149 hasRelatedWork W4286762368 @default.

• next